Publication date: Jun 04, 2025
The COVID-19 public health emergency (PHE) ended in May 2023, but limited information exists on the continued risk of severe COVID-19 among the immunocompromised (IC) population and those with certain chronic medical conditions (CMCs). This study aimed to assess the risk of moderate/severe COVID-19 and compare associated healthcare resource utilization (HCRU) and costs for IC vs. general populations, with a focus on increasing age and CMC burden in the IC population. This retrospective observational cohort study analyzed claims from the Healthcare Integrated Research Database (HIRD) for individuals with a COVID-19 diagnosis or positive test between March 2023 and February 2024. Patients were followed until the study’s end, disenrollment, or death. Propensity scores were calculated using binomial logistic regression to adjust for confounding when comparing the IC and general population groups. The IC cohort was divided into five subgroups based on age (
| Concepts | Keywords |
|---|---|
| Covid | Chronic medical conditions |
| Death | COVID-19 |
| February | Immunocompromise |
| Immunocompromised |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | emergency |
| drug | DRUGBANK | L-Phenylalanine |
| disease | MESH | death |
| disease | MESH | Long Covid |